Compare DBD & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBD | IDYA |
|---|---|---|
| Founded | 1859 | 2015 |
| Country | United States | United States |
| Employees | N/A | 145 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2023 | 2019 |
| Metric | DBD | IDYA |
|---|---|---|
| Price | $52.02 | $25.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | ★ $85.00 | $50.15 |
| AVG Volume (30 Days) | 343.9K | ★ 1.1M |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 677.27 | 61.90 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $3,805,700,000.00 | $218,710,000.00 |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $2.54 | $186.04 |
| P/E Ratio | $65.29 | ★ N/A |
| Revenue Growth | 1.46 | ★ 3024.43 |
| 52 Week Low | $49.77 | $25.75 |
| 52 Week High | $92.09 | $42.68 |
| Indicator | DBD | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 32.61 | 24.75 |
| Support Level | N/A | N/A |
| Resistance Level | $85.54 | $29.74 |
| Average True Range (ATR) | 2.43 | 1.73 |
| MACD | -0.50 | -0.54 |
| Stochastic Oscillator | 18.84 | 0.47 |
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.